#	Pagina
attuale pagina	/open-h2020/projects/218284/index.html

Opendata, web and dolomites

PATH-TOX SIGNED

Artificial Intelligence to transform Drug and Chemical safety testing

Total Cost €

EC-Contrib. €

Partnership

Views

PATH-TOX project word cloud

Explore the words cloud of the PATH-TOX project. It provides you a very rough idea of what is the project "PATH-TOX" about.

date looming expensive pathological prototype components big aided tissue irish cloud artificial drugs direct mainly framework consuming cros toxicology ltd liver optimise diagnostic tools tissues streamline intelligence upfront thousands benchmarking time knock image market validation regards computer animals pathology pharma competitors once compare animal abnormal sme individual effect tests routinely markets lack performance customers deciphex ai automatically manual swiss reducing hence solutions perform tox normal pharmaceuticals safety data expand janssen toxicity workflow yields global manually fit purpose discovery led pathologist review belgium undergo crisis worldwide accelerate interface veterinary competition engine risky trained pathologists patholytix sections drug

Project "PATH-TOX" data sheet

The following table provides information about the project.

Coordinator	JANSSEN PHARMACEUTICA NV Organization address address: TURNHOUTSEWEG 30 city: BEERSE postcode: 2340 website: www.janssenpharmaceutica.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Belgium [BE]
Total cost	2˙935˙000 €
EC max contribution	2˙054˙499 € (70%)
Programme	1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
Code Call	H2020-EIC-FTI-2018-2020
Funding Scheme	IA
Starting year	2018
Duration (year-month-day)	from 2018-11-01 to 2020-10-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	JANSSEN PHARMACEUTICA NV JANSSEN PHARMACEUTICA NV Organization address address: TURNHOUTSEWEG 30 city: BEERSE postcode: 2340 website: www.janssenpharmaceutica.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BEERSE)	coordinator	134˙531.00
2	DECIPHEX LIMITED DECIPHEX LIMITED Organization address address: 7 GARRAI NA GCRANN city: MORNINGTON MEATH postcode: n.a. website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IE (MORNINGTON MEATH)	participant	1˙626˙843.00
3	PDS PATHOLOGY DATA SYSTEMS AG PDS PATHOLOGY DATA SYSTEMS AG Organization address address: DURRENHUBELSTRASSE 9 city: PRATTEIN postcode: 4133 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CH (PRATTEIN)	participant	293˙125.00

Map

Project objective

Drug discovery is a time consuming, expensive and risky process. Each drug to market must undergo safety/ toxicity testing in animals which yields thousands of tissue sections that currently must be assessed manually by a trained veterinary pathology. However, there is a looming crisis due to the lack pathologists.

The PATH-TOX consortium is led by Irish SME, Deciphex Ltd, and includes key partners such as Janssen Pharmaceuticals in Belgium and Pathology Data Systems Ltd a Swiss based SME. They are creating PATHOLYTIX-TOX a computer aided diagnostic system to streamline the pathology review process. Using state-of-the-art artificial intelligence (AI) image analysis tools it will automatically identify the normal and abnormal tissues upfront, allowing the pathologist to focus mainly on the abnormal cases, hence accelerate workflow.

To date, we have built a working prototype of the image analysis engine, which can identify abnormal tissue in liver. In this project we will optimise the engine further to improve performance and expand its use into other tissues. We will also develop other features such as the user interface, data management and cloud framework. Once developed, we will perform a comprehensive validation and benchmarking study to compare to manual pathology assessment.

There is a large, growing, global target market for PATHOLYTIX-TOX. Pharma and CROs worldwide routinely perform thousands of animal toxicology tests each year, who are potential customers. With regards to competitors, there is no direct competition. Competitors offer individual components of the pathological workflow, not fit-for-purpose solutions for the toxicology pathology market.

Overall, PATHOLYTIX would have a big impact on drug development, by reducing the time required for pathology review and associated costs. This should have a knock on effect for the global and EU markets, reducing time and cost for new drugs to get to market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PATH-TOX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PATH-TOX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.1.)

Bio-LP-1 (2020)

A novel rapid environmental test for the human pathogen Legionella

PAV-DT (2019)

A disruptive technology that enables low cost real-time monitoring of road pavement condition by any ordinary vehicle circulating on the road, and automatically designs plans for predictive maintenance.